ClearPoint Neuro (CLPT) to Release Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect ClearPoint Neuro to post earnings of ($0.22) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $13.58 on Wednesday. ClearPoint Neuro has a twelve month low of $9.76 and a twelve month high of $30.10. The firm’s 50 day moving average price is $13.98 and its 200 day moving average price is $15.50. The firm has a market cap of $385.94 million, a PE ratio of -16.17 and a beta of 1.01. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.56 and a current ratio of 6.37.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CLPT. Wall Street Zen cut shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ClearPoint Neuro has an average rating of “Hold” and an average price target of $9.00.

Insider Activity

In related news, CEO Joseph Burnett sold 2,943 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $15.57, for a total transaction of $45,822.51. Following the transaction, the chief executive officer directly owned 214,116 shares in the company, valued at approximately $3,333,786.12. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.11% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CLPT. Millennium Management LLC lifted its stake in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after buying an additional 452,043 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after purchasing an additional 127,823 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of ClearPoint Neuro by 35.4% in the second quarter. JPMorgan Chase & Co. now owns 32,790 shares of the company’s stock worth $392,000 after acquiring an additional 8,581 shares during the last quarter. Legal & General Group Plc acquired a new stake in ClearPoint Neuro in the second quarter valued at approximately $35,000. Finally, Rhumbline Advisers bought a new stake in shares of ClearPoint Neuro during the second quarter worth about $450,000. 30.08% of the stock is currently owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.